Fueling Clinical Innovation and Growth
Creating cardiovascular care solutions for value-based by outcomes incorporating inclusive healthcare strategies
Creating cardiovascular care solutions for value-based by outcomes incorporating inclusive healthcare strategies
AI, machine learning, and wearables in transforming CV care
Innovations that help identify CVD risk early can improve patient outcomes, streamline care delivery, reduce healthcare spending, and solve for health inequities
Innovation that ensures techquity will facilitate broad adoption
Latest innovations: diagnostic tools, treatment, and digital health technologies provide increased access to care allowing for earlier diagnosis and better opportunities for disease management
Business and strategic opportunities for market expansion
Investments in research and development and partnerships that leverage cutting-edge technologies to address unmet clinical needs and improve patient access to quality care through earlier identification
Solution
Innovation and commercialization of technology will not be enough. Strategic plans that address operational gaps in care and alignment with clinical needs will be necessary to drive adoption. Developing AI based predictive risk models that demonstrate value to the overall healthcare system while reducing data fatigue for clinicians will drive adoption of new technologies.
Impact
Adopting solutions that provide AI-based predictive risk models that lead to earlier detection, improved guideline-directed medical management and treatment, with fewer medical errors can contribute to reduced healthcare resource utilization and meeting the goals of value-based care.
Factors such as a rapidly aging and more diverse population combined with increased risk factors including hypertension and obesity will lead to CVD costs to triple by 2050, reflecting a cost of $1.8T. Over 61% of adults in the US will experience some form of CVD.
Files coming soon.
Solution
Expand the use of digital health solutions and telemedicine platforms to extend healthcare access to more patients. Care pathways that incorporate these solutions along with patient education at the point of care have greater potential for easier diagnosis and intervention.
Impact
Increased access to care, reducing unnecessary office and emergency visits, and avoiding hospitalizations will work towards reducing overall healthcare spending and help achieve value based care and accountable care organization goals.
Patients with established CVD accounted for 42.8% of total inpatient hospitalization costs. This number does not account for patients who entered the healthcare system with undiagnosed CVD or the costs of subsequent hospitalizations. Implementing technology and solutions that enable earlier diagnosis and treatment will be crucial. Disrupting existing models to extend care beyond tertiary centers must be developed as digital health solutions are introduced.
Nichols GA, Bell TJ, Pedula KL, O'Keeffe-Rosetti M. Medical care costs among patients with established cardiovascular disease. Am J Manag Care. 2010 Mar;16(3):e86-e93. PMID: 20205493.
Files coming soon.
Solution
Create partnerships and make research investments that explore adjacent diseases with cardiovascular comorbidities.
Impact
More inclusive care strategies to address the impacts of CVD across various specialities and prevent broader adverse effects on health and outcomes.
Neurocardiology
Cardiovascular disease plays a significant role in the development of dementia or Alzheimer's disease (AD). Reduced blood flow, chronic inflammation, hypertension, atherosclerosis, atrial fibrillation (AF), and stroke are all associated with dementia and AD, although a direct link has not yet been made. * Studies have shown 24-hour blood pressure variability is associated with cognitive decline. **
In the U.S., 11.3% of cancer patients died from CVD. *** Compared to patients of similar age, individuals with cancer had a 4-fold increased risk of death from CVD in the first year of diagnosis and continue to have an increased risk throughout their lifetime.****
The U.S. has the highest maternal mortality rate in all developed countries,***** with 80% of these categorized as preventable according to the CDC.****** Cardiovascular conditions are the most common cause of pregnancy related deaths.**
Some immune-mediated inflammatory diseases carry a 4-fold higher likelihood of cardiovascular risk.* Cardiovascular death is responsible for 30-50% of all deaths in patients with rheumatoid arthritis.*
Files coming soon.
Understanding the current and future trends to ensure product development and commercialization will uniquely address the largest unmet needs in the field. Early and strategic engagement of Key Opinion Leaders (KOLs) to leverage visibility, support activities, and provide medical and scientific guidance. Early engagement and utilization that can be leveraged with payers.
Through partnerships, ensure data integration can improve accuracy and can be used for early, personalized treatment plans, disease prediction, and provide guideline based recommendations at the point of care.
Collaboration with other tech and device companies as well as academic institutions, to accelerate innovation and adoption. Partnering with public health to address some of the most challenging and costly concerns.
Engaging KOLs to facilitate medical education at meetings of profession societies and other key organization meetings. Ensure engagement with fellowship programs. Education activities will chart a path toward market development and penetration.
Medical Affairs leader passionate about reducing health disparities through innovative care delivery and workflow solutions. Expert in addressing unmet needs of patients, providers, and organizations, introducing disruptive products that enhance operational efficiency and deliver sustainable outcomes. With deep expertise across the produc
Medical Affairs leader passionate about reducing health disparities through innovative care delivery and workflow solutions. Expert in addressing unmet needs of patients, providers, and organizations, introducing disruptive products that enhance operational efficiency and deliver sustainable outcomes. With deep expertise across the product lifecycle and nuanced cardiovascular workflows, excels in integrating technology into clinical practice. Recognized as a strategic connector who fosters trust, aligns diverse stakeholders, and drives impactful collaboration. Forward-thinking leader committed to elevating healthcare through meaningful progress.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.